Search ARM

2018 Annual Report


This quarterly data report details industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.


This quarterly data report details industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.

Global Landscape

906+

Regenerative Medicine Companies
Worldwide, Including Gene and
Cell Therapies, and Tissue Engineering
Therapeutic Developers

Financings

Total 2018 Global Financings

Total Global Financing

$13.3 Billion

 73%

Increase from 2017

Gene & Gene-modified
Cell Therapy

$9.7 Billion

 64%

Increase from 2017

Cell Therapy

$7.6 Billion

 64%

Increase from 2017

Tissue Engineering

$937 Million

 258%

Decrease from 2017

Total Global Financings by Type

Clinical Trials

Number of Clinical Trials Utilizing Specific
RM / AT Technology:

EOY 2018

Gene Therapy
Gene-Modified
Cell Therapy
Cell Therapy
Tissue Engineering